Giá Alphamab Oncology (09966.HK)

Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu and currently employs 484 full-time employees. The company went IPO on 2019-12-12. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.